As the number of confirmed cases of COVID-19 surges past 2.5 million globally with deaths at 177,115 (as of April 22), clinicians and pathologists are struggling to understand the damage its wrought. They realize that although the lungs are ground zero, its reach can extend to many organs: Its viciousness is breathtaking and humbling.

When an infected person expels virus-laden droplets and someone else inhales them, this coronavirus enters the nose and throat. It finds a welcome home in the lining inside the nose. Cells there are rich in a surface receptor (pandikit) called angiotensin-converting enzyme 2 (ACE2), which the virus requires to enter the cell. Once inside, the virus hijacks the cells reproductive machinery, making myriad copies of itself and invading new cells.

A virus can copy anything it wants and can even make itself comfortably adapt to the environment where it chooses to stay while killing the normal cells of your body.

As it multiplies, an infected person may shed copious amounts of it, especially during the first week or so. Symptoms may be absent or the infected may develop fever, dry cough, sore throat, loss of smell and taste, or head and body aches.

Photo from dermatologyadvisor.com

If the immune system does not fight back, the virus then marches down the windpipe to attack the lungs, where it can turn deadly. This is because the thinner, distant branches of the lungs respiratory tree end in tiny air sacs called alveoli, which are also rich in ACE2 receptors. The virus can attach itself again and wreak havoc.

Normally, oxygen crosses the air sacs into the capillaries, tiny blood vessels that lie beside them. The oxygen is then carried to the rest of the body. COVID infection disrupts this healthy oxygen transfer. The front liners of our immune system, white blood cells, release inflammatory molecules called chemokines that summon more immune cells to target and kill virus-infected cells, leaving a stew of fluid and dead cells pus behind. This results in pneumonia: coughing, fever and rapid, shallow breathing.

Some COVID-19 patients recover, sometimes with no support other than oxygen. But others deteriorate, often suddenly, developing a condition called acute respiratory distress syndrome (ARDS). The oxygen levels in their blood plummet and they struggle even harder to breathe. On X-rays and computed tomography scans, their lungs are riddled with white opacities (areas without air). Commonly, these patients end up on ventilators. Many die. Autopsies show their alveoli became stuffed with fluid, white blood cells, mucus and the detritus of destroyed lung cells.

The invaders impact does not end there. The bodys response to destroy it can injure even more organs. Clinicians suspect that the driving force in many gravely ill patients downhill trajectories is a disastrous overreaction of the immune system, or cytokine storm.

Cytokines are chemical signaling molecules that guide a healthy immune response, but in a cytokine storm, levels of certain cytokines soar far beyond whats needed, and immune cells start to attack healthy tissues. Blood vessels leak, blood pressure drops, clots form and catastrophic organ failure can ensue.

Cardiovascular damage occurs.Kidneys, liver, blood vessels, the skin and brain are affected as well.Blood clots can break apart and land in the lungs, blocking vital arteries a condition known as pulmonary embolism that can kill COVID-19 patients.

Brain incursion via the nose can reach the olfactory bulb, inducing loss of smell. Clots from arteries can also lodge in the brain, causing a stroke.

Some people with COVID-19 briefly lose consciousness. Doctors wonder whether in some cases, infection depresses the brain stem reflex that senses oxygen starvation, which explains why some patients are not gasping for air, despite dangerously low blood oxygen levels.

COVID-19 can also infect the lining of the lower digestive tract, where ACE2 receptors are abundant. Viral RNA has been found in as many as 53 percent of patients stool samples, raising the unsettling possibility that it could be passed on through feces. As of this writing, theres no evidence that fecal transmission can occur.

Others develop conjunctivitis pink, watery eyes, others had elevated levels of enzymes indicating injury to the liver or bile ducts.But this may also be due to drugs or an over-driven immune system.

Lastly, cutaneous or skin manifestations have been reported in COVID-19 patients:

Generalized sporadic red rasherupting along the trunk or extremities that are typically transient and resolve on their own. They may be very itchy. Sometimes this can be confused with dengue.

Petechiae.Pinpoint bleeding underneath the skin that does not disappear when pressure is applied.

Generalized urticaria are wheal-like rashes that can coalesce together to form large plaques.

Vesicular eruptionmimicking varicella (chicken pox) blisters.

Vasculopathic presentations. Frostbite-like lesions on the feet and hands multifocal, often asymmetric patches manifest in two to three days. It then evolves to the formation of blisters, to bruises or necrosis (black, dead skin).Sometimes they appear as red, purplish bumps on the feet and hands that evolve into hemorrhagic bullae, or develop a blackish crust due to damage to the lining of the blood vessels, leading to clots that block blood vessels. These can lead to ulcer or gangrene formation, and death.

Acute hemorrhagic edema in infants.Sudden swelling of limbs with patches of bruises in a well-appearing child, before the rash dissipates in 48 hours along with the swelling.

Erythematouslarge patches scattered all over the body that may be slightly itchy.

Localized extreme pruritus,like in the wrist or ankle areas only.

This map of the devastation that COVID-19 can inflict on the body is still just a sketch. It will take years of painstaking research to sharpen the picture of its reach.

* * *

For inquiries, call 8401-8411 or 0917-497-6261, 0999-883-4802 or email gc_beltran@yahoo.com. Follow me on facebook@dragracebeltran.

Follow this link:
COVIDs devastation on the body includes the skin - Philippine Star

Recommendation and review posted by Bethany Smith

Cosmetic Skin CareMarketBusiness Insights and Updates:

The latest Marketreport by a Data Bridge Market Researchwith the title[Global Cosmetic Skin CareMarket Industry Trends and Forecast to 2026].The new report on the worldwide Cosmetic Skin CareMarketis committed to fulfilling the necessities of the clients by giving them thorough insights into the Market. The various providers involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.The reports provide Insightful information to the clients enhancing their basic leadership capacity identified.Exclusive information offered in this report is collected by analysis and trade consultants.

Global cosmetic skin care market is set to witness a substantial CAGR of 5.5% in the forecast period of 2019- 2026.

Cosmetic skin care is a variety of products which are used to improve the skins appearance and alleviate skin conditions. It consists different products such as anti- aging cosmetic products, sensitive skin care products, anti- scar solution products, warts removal products, infant skin care products and other. They contain various ingredients which are beneficial for the skin such as phytochemicals, vitamins, essential oils, and other. Their main function is to make the skin healthy and repair the skin damages.Get PDF Samplecopy(including TOC, Tables, and Figures) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cosmetic-skin-care-market

Thestudy considers the Cosmetic Skin CareMarketvalue and volume generated from the sales of the following segments:Major Marketmanufacturerscovered in the Cosmetic Skin CareMarketare:LOral, Unilever, New Avon Company, Este Lauder Companies, Espa, Kao Corporation, Johnson & Johnson Services, Inc., Procter & Gamble, Beiersdorf, THE BODY SHOP INTERNATIONAL LIMITED, Shiseido Co.,Ltd., Coty Inc., Bo International, A One Cosmetics Products, Lancme, Clinique Laboratories, llc., Galderma Laboratories, L.P., AVON Beauty Products India Pvt Ltd, Nutriglow Cosmetics Pvt. Ltd, Shree Cosmetics Ltd

By Product

By Application

By Gender

By Distribution Channel

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-cosmetic-skin-care-market

Based on regions, the Cosmetic Skin CareMarketis classified into North America, Europe, Asia- Pacific, Middle East & Africa, and Latin AmericaMiddle East and Africa (GCC Countries and Egypt)North America (United States, Mexico, and Canada)South America(Brazil, Argentina etc.)Europe(Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific(Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Market Drivers:

Market Restraints:

Key Developments in the Market:

Key Benefits for Cosmetic Skin CareMarket:

Enquire Here For Discount Or Cosmetic Skin CareMarket Report Customization@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cosmetic-skin-care-market

About Us:Data Bridge Marketresearch endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process Data Bridge set forth itself as an unconventional and neoteric Marketresearch and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best Marketopportunities and foster efficient information for your business to thrive in the Market.We ponder into the heterogeneous Markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the Markettrends. Data Bridge delves into the Markets across Asia, North America, South America, Africa to name few.

Contact Us:Data Bridge MarketResearchUS: +1-888-387-2818

Read the original:
Cosmetic Skin Care Market to see impressive Growth by 2027| Leading Companies- L'Oral, Unilever, Espa, Kao, Johnson & Johnson - Cole of Duty

Recommendation and review posted by Bethany Smith

(L-R) Professor Geoff Lindeman and Professor Jane Visvader

are joint heads of the Institutes ACRF Stem Cells and Cancer

Division.

Using advanced three-dimensional (3D) imaging techniques, the team observed how the immune cells monitor for threats in the mammary ducts and help to maintain tissue health by eating up dying milk-producing cells needing to be cleared away once lactation stops.

The preclinical research was led by Walter and Eliza Hall Institute researchers Dr Caleb Dawson, Professor Geoff Lindeman and Professor Jane Visvader, along with Dr Anne Rios who is now based at the Princess Mxima Center for Pediatric Oncology, Netherlands. It was published today in the journal Nature Cell Biology.

Institute breast cancer researcher Dr Caleb Dawson.

The mammary gland is a dynamic organ that undergoes dramatic remodelling throughout life. The branching ducts bloom to form milk-producing factories in lactation, which must be eliminated once lactation stops. Mammary ducts are of particular interest to breast cancer researchers because this site is prone to cancer development.

While exploring mammary ducts using high-resolution imaging techniques, Dr Dawson said the researchers were surprised to discover a new immune cell type, and its specific role in maintaining healthy, intact breast tissue.

We discovered an entirely new population of specialised immune cells, which we named ductal macrophages, squeezed in between two layers of the mammary duct wall.

We were excited to find that these cells play an essential role at a pivotal point in mammary gland function called involution when lactation stops, milk-producing cells die and breast tissue needs to remodel back to its original state, he said.

We watched incredulously as the star-shaped ductal macrophages probed with their arms and ate away at dying cells. The clearing action performed by ductal macrophages helps redundant milk-producing structures to collapse, allowing them to successfully return to a resting state, Dr Dawson said.

When the researchers later removed ductal macrophages from the mammary ducts they discovered that no other immune cells were able to swiftly carry out this essential process.

Most organs in the body including the brain, liver, lung, skin and intestine have their own population of macrophages a name of Greek origin that means big eater. These cells play important roles in regulating infection, inflammation and organ function within their sites of residence.

Professor Visvader said discovering mammary duct-specific macrophages was a remarkable step forward in understanding how the immune system interacted with the ductal network and impacted upon mammary gland development.

As breast cancer researchers, there is a need to understand which cells are doing what, so that we can identify how these intricate cellular processes become dysregulated, such as in the case of breast cancers, she said.

More than 19,000 Australians are diagnosed with breast cancer every year. It is the most common cancer in Australian women.

Dr Dawson said that going forward, the team hoped to explore the function of ductal macrophages at different stages of mammary gland development, such as the transitions into adulthood and pregnancy.

We also want investigate the role that these duct-specific immune cells play in helping cancer to grow and spread.

Ductal macrophages are spread throughout the mammary ducts. As cancer grows, these macrophages also increase in number. We suspect that theres the potential for ductal macrophages to inadvertently dampen the bodys immune response, which would have dangerous implications for the growth and spread of cancer in these already prone sites, Dr Dawson said.

Professor Visvader said the teams ultimate goal was to understand these cells enough to manipulate them.

Given that tumour macrophages likely promote growth of the tumour, blocking their activity could serve as a treatment strategy for breast cancer, she said.

The research was supported by the National Health and Medical Research Council, the National Breast Cancer Foundation, the Australian Cancer Research Foundation, The Qualtrough Cancer Research Fund, Cure Cancer Australia and the Victorian Government.

Follow this link:
New type of immune cell discovered in breast ducts - Mirage News

Recommendation and review posted by Bethany Smith

DetailsCategory: DNA RNA and CellsPublished on Monday, 27 April 2020 17:10Hits: 524

BOSTON, MA, USAandLONDON, UK I April 27, 2020 IOrchard Therapeutics(Nasdaq: ORTX), a global gene therapy leader, today announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). The study is designed to evaluate safety, tolerability and clinical efficacy and is intended to enroll up to five patients between three months and 24 months of age who will be followed for three years. The study also contains a number of key secondary outcome measures such as overall survival, cognition and behavior to help inform future clinical development of HSC gene therapy in this indication.

MPS-IIIA, also known as Sanfilippo syndrome type A, is a rare, inherited neurometabolic disorder caused by genetic mutations that leads to the buildup of sugar molecules called mucopolysaccharides in the body, resulting in progressive intellectual disability and loss of motor function. Children born with MPS-IIIA rarely live past adolescence or early adulthood, and no approved therapies currently exist to treat the disease.

I am very encouraged that we, together with our research and clinical collaborators in Manchester, could achieve this important milestone in our efforts to develop a gene therapy for MPS-IIIA despite the current, challenging global health circumstances, saidBobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. It is a testament to the dedication of our collective teams and underscores the truly dire, life-limiting nature of the disease for affected children and their families. This study adds to Orchards clinical pipeline of HSC gene therapies for the treatment of severe neurometabolic disorders and further demonstrates the potential of our platform approach.

About MPS-IIIAMucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A) is a rare and life-threatening metabolic disease. People with MPS-IIIA are born with a mutation in theN-sulphoglucosamine sulphohydrolase (SGSH)gene, which, when healthy, helps the body break down sugar molecules called mucopolysaccharides. The buildup of mucopolysaccharides in the brain and other tissues leads to intellectual disability and loss of motor function. MPS-IIIA occurs in approximately one in every 100,000 live births. Life expectancy of children born with MPS-IIIA is estimated to be between 10-25 years.

About OrchardOrchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically-modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. The company has one of the deepest gene therapy product candidate pipelines in the industry and is advancing seven clinical-stage programs across multiple therapeutic areas, including inherited neurometabolic disorders, primary immune deficiencies and blood disorders, where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

SOURCE: Orchard Therapeutics

See the original post:
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA) |...

Recommendation and review posted by Bethany Smith

ELEVECTA(R) takes viral vector manufacturing to the next level to serve the rapidly growing market of gene therapy applications

Growing serum-free in suspension, ELEVECTA(R) producer cell lines enable fully scalable high-performance AAV vector production based on standardized processes widely used in industry for monoclonal antibody production

With all components stably integrated into one cell, the ELEVECTA(R) technology provides large scale AAV production without expensive cGMP-grade plasmids and complex transient transfection steps

COLOGNE, GERMANY / ACCESSWIRE / April 28, 2020 / CEVEC Pharmaceuticals GmbH (CEVEC), the leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from research to production scale, today announced the launch of the ELEVECTA(R) platform, a unique technology to manufacture AAV (Adeno-associated viral) vectors at large scale. With the launch, CEVEC is the first and only provider on the market to offer AAV gene therapy vector manufacturing technology on the basis of fully stable producer cell lines.

The patent-protected technology has been proven by CEVEC in pilot projects with several partners and is now commercially available for Pharma and Biotech companies running gene therapy programs from late research to all clinical phases.

ELEVECTA(R) takes AAV vector manufacturing to the next level

With the ELEVECTA(R) technology, CEVEC has taken a unique approach based on producer cell lines, which have all necessary elements for AAV production stably integrated in one cell. Up to now, manufacturing of AAV - the most widely used vector for in vivo gene therapy - has required expensive transfection reagents and cGMP-grade plasmids. ELEVECTA(R) now overcomes these limitations and enables efficient, high-performance AAV production from one cell line in consistent quality. The technology can easily be implemented in bioprocess development and large-scale GMP manufacturing facilities running standard suspension bioreactor equipment widely used in industry for monoclonal antibody and recombinant protein production.

Story continues

"The launch of ELEVECTA(R) forms a milestone on the way into a new era of viral vector manufacturing as it provides a solution for one of the major challenges in gene therapy development. By closing the production gap and providing the necessary quantities of viral vectors, it paves the way to address more common indications such as Alzheimer's, Parkinson's, or Rheumatoid Arthritis as well as therapies that require larger doses," said Nicole Faust, CEO of CEVEC Pharmaceuticals. "With this launch, we provide pharmaceutical and biotechnology companies with the opportunity to benefit right from the beginning from what we believe is the future for viral vector production. The superior features in terms of scalability, production efficiency and robustness of our stable producer cell lines position CEVEC at the leading edge in the rapidly growing field of gene therapy vector manufacturing."

ELEVECTA(R) closes the production gap in gene therapy viral vector production

Gene therapy is considered to be the most effective and often only treatment option for many severe and life-threatening diseases. Moreover, in a growing number of indications, gene therapies for the first time offer the opportunity to cure a disease. In addition, as gene therapy is moving from rare and ultra-rare to more common indications with larger patient numbers and systemic treatments, larger amounts of vector material are required. Consequently, production processes are needed that are fit for this purpose, enabling the manufacture of the necessary quantities of viral vectors with high yield and consistent quality.

ELEVECTA(R) - A concept to match the customers' needs

CEVEC's newly launched ELEVECTA(R) technology overcomes the limitations of existing manufacturing methods such as restricted scalability, time-consuming and cost-intensive material sourcing and complex production processes. ELEVECTA(R) technology is based on a patent-protected, fully documented human suspension cell line developed and optimized by CEVEC.

The ELEVECTA(R) technology works for any combination of serotype-specific capsid and therapeutic gene of interest. The stable integration of these components into the cell results in cell lines designed to produce highly functional AAV vectors. Custom-made ELEVECTA(R) Producer Cell Lines are available as research cell banks or as fully tested cGMP Master Cell Banks for manufacturing of clinical and commercial material.

CEVEC launches the technology in various formats matching the needs of customers in different development phases, with focus on gene therapy programs from late research to any clinical phases. CEVEC offers cell line development services to match the specific needs of gene therapy programs and various license packages from research and development to commercial manufacturing.

Further information:

To get a deeper insight into the ELEVECTA(R) technology register for a webinar on May 5th, at 5:00 p.m. CEST (11:00 a.m. EST) featuring CEVEC's CSO, Dr. Silke Wissing, talking about "Stable AAV producer cell lines: elevating vector manufacturing" and/or visit the ELEVECTA(R) web page.

In addition, you can meet CEVEC's management at the 23rd ASGCT virtual Annual Meeting taking place from May 12 - 15, 2020. During this event, interested parties can listen to the ELEVECTA(R) poster presentations and visit the CEVEC virtual booth. Please request a virtual meeting through the ASGCT webpage or directly contact CEVEC under bizdev@cevec.com.

About CEVEC:

CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced bio-therapeutics from R&D to manufacturing scale. The company's product portfolio comprises platform technologies for gene therapy viral vectors (AAV, Adenoviral vectors, Lentiviral vectors,), vaccines and complex recombinant proteins. With the ELEVECTA(R) Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using producer cell lines with all necessary components stably integrated into the cell. The technology is based on suspension cells and does not require any expensive transfection reagents and cGMP plasmids. CEVEC's CAP(R) Technology based on human suspension cells is the ideal production platform for RCA-free Adenoviral vectors, Lentiviral vectors, Oncolytic viruses, Viral vaccines and exosomes. With the CAP-Go(R) Technology CEVEC provides a solution to the increasing need for recombinant production of complex and highly glycosylated protein molecules, including laminins, coagulation factors and plasma proteins.

For more information, please visit the Company's website.

Follow CEVEC on LinkedIn and Twitter.

Contact:

SOURCE: CEVEC Pharmaceuticals GmbH

View source version on accesswire.com: https://www.accesswire.com/587337/CEVEC-Announces-the-Launch-of-the-ELEVECTAR-Platform--the-Stable-Producer-Cell-Line-Technology-for-AAV-Gene-Therapy-Vectors

See the original post here:
CEVEC Announces the Launch of the ELEVECTA(R) Platform - the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors - Yahoo Finance

Recommendation and review posted by Bethany Smith

Affinia Therapeutics proprietary AAV vector technology to be used in Vertexs genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis

BOSTON & WALTHAM, Mass.--(BUSINESS WIRE)-- Vertex PharmaceuticalsIncorporated (Nasdaq:VRTX) and Affinia Therapeutics announced today that the two companies have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids to deliver transformative genetic therapies to people with serious diseases. Affinia Therapeutics proprietary AAVSmartLibrary and associated technology provides capsids for improved tissue tropism, manufacturability and pre-existing immunity. The collaboration will leverage Affinia Therapeutics capsid engineering expertise and Vertexs scientific, clinical and regulatory capabilities to accelerate the development of genetic therapies for people affected by Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and cystic fibrosis (CF).

This collaboration with Affinia Therapeutics will enhance our existing capabilities in discovering and developing transformative therapies for people with serious diseases, said Bastiano Sanna, Executive Vice President and Chief of Cell and Genetic Therapies at Vertex. Affinia Therapeutics innovative approach to the discovery and design of AAV capsids brings yet another tool to our Vertex Cell and Genetic Therapies toolkit, and were excited to partner with them to bring together their technology platform with our research and development expertise.

At Affinia Therapeutics, were setting a new standard in genetic therapy by leveraging our platform to methodically engineer novel AAV vectors that have unique therapeutic properties, said Rick Modi, Chief Executive Officer. Vertex is an established leader in developing transformative medicines for genetic diseases and renowned for its scientific rigor. We are thankful for the scientific validation this partnership brings and look forward to working closely with them to advance life-changing, differentiated genetic therapies and make a meaningful difference to those affected by these diseases.

About the Collaboration

Under the terms of the agreement, Affinia Therapeutics will apply its vector design and engineering technologies to develop novel capsids with improved properties. The agreement provides Vertex an exclusive license under Affinia Therapeutics proprietary technology and intellectual property (IP) in DMD and DM1 with an exclusive option to license rights for CF and an additional undisclosed disease. The scope of the agreement covers all genetic therapy modalities in these diseases. Affinia Therapeutics will be eligible to receive over $1.6 billion in upfront and development, regulatory and commercial milestones, including $80 million in upfront payments and research milestones that will be paid during the research term, plus tiered royalties on future net global sales on any products that result from the collaboration. Affinia Therapeutics will be responsible for the discovery of capsids that meet certain pre-determined criteria. Vertex will be responsible for and will fund the design and manufacturing of genetic therapies incorporating the selected capsids, preclinical and clinical development efforts, and commercialization of any approved products in the licensed diseases.

About Affinia Therapeutics

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need. http://www.affiniatx.com.

About Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) a rare, life-threatening genetic disease and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit http://www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, Dr. Sannas statements in the second paragraph of the press release, Mr. Modis statements in the third paragraph of the press release, and statements regarding future activities of the parties pursuant to the collaboration. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent Vertex's beliefs only as of the date of this press release and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. Those risks and uncertainties include, among other things, Vertex may not realize the anticipated benefits of the collaboration, and the other risks listed under Risk Factors in Vertex's annual report and quarterly reports filed with the Securities and Exchange Commission and available through the company's website at http://www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005151/en/

Read more from the original source:
Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies -...

Recommendation and review posted by Bethany Smith

A research team at the Seoul National University Bundang Hospital (SNUBH) has released the results of phase 1 clinical trial of a new treatment that kills cancer cells of pancreatic cancer patients. In the trial, the researchers tested a method that used genetically modified adenovirus, in which two different cancer treatment genes are inserted, on patients with irresectable pancreatic cancer.

Pancreatic cancer is deadly cancer that people fear most because of its poor prognosis, as shown by a five-year survival rate of only about 12.2 percent.

Patients with locally advanced pancreatic cancer, in which cancer cells spread to nearby lymph nodes and blood vessels, face difficulty in receiving surgery and growing resistance to anticancer treatment, resulting in the abandonment of therapy. With the recent rapid development of cancer treatments, however, anticancer therapies based on precision medicine get the spotlight, and new therapies are being studied for pancreatic cancer.

These new therapies are drawing attention as to whether they provide hope for patients with pancreatic cancer whose vein or artery.

The research team, led by Professors Hwang Jin-hyuk and Lee Jong-chan, studied to confirm the safety and possibility of a new way to treat non-resectable pancreatic cancer patients with adenovirus as a gene carrier in nine patients for two years from August 2018.

The team inserted an adenovirus that can create two enzymes -- cytosine deaminase and tyrosine kinase -- to pancreatic cancer patients through endoscopic ultrasonography. The injected adenovirus naturally disappears in healthy cells and multiplies only in pancreatic cancer cells due to the primary effect of genetic modification.

After the injection, if the patient takes an oral medication without an anticancer effect, the drug meets the enzyme of the adenovirus in the pancreatic cancer cell and turns into an anticancer reagent. The changed virus, which can survive in cancer cells, then kills only pancreatic cancer cells.

The study result showed that drug administration to the nine pancreatic cancer patients did not show significant side effects during 12 weeks of treatment, proving to be a relatively safe medicine. Pancreatic cancer did not progress further in all nine patients who have been taking 12 weeks of treatment. The median progression-free survival, which is used as an index for evaluating the efficacy, was 11.4 months.

The study was meaningful as we could confirm the safety and potential of new gene therapy via the phase 1 trial, Professor Hwang said. We not only confirmed that the patients could be treated by inserting the modified genes to pancreatic cancer but also saw the effect of slowing the progression of pancreatic cancer, providing a basis for follow-up studies.

The trial results were published in the latest issue of Gastrointestinal Endoscopy, a U.S. journal with top authority in the endoscopic field.

shim531@docdocdoc.co.kr

< Korea Biomedical Review, All rights reserved.>

Excerpt from:
SNUBH team finds modified adenovirus halts pancreatic cancer progression - Korea Biomedical Review

Recommendation and review posted by Bethany Smith

The ongoing COVID-19 pandemic and the worldwide reaction to it has compelled companies to radically rethink their strategies and the way they operate. We salute the industry experts helping companies survive and sustain in this pandemic. At Healthcare Intelligence Market Analysts, are undertaking continuous efforts to provide analysis of the COVID-19 impact on the Gene Therapy Technologies Market. We are working diligently to help companies take rapid decisions by studying.

The global Gene Therapy Technologies Market is segmented on the basis of product & services, application, end user and geography. On the basis of product & services, the Gene Therapy Technologies Market is segmented into consumables, software and services. On the basis of application, the Gene Therapy Technologies Market is segmented into diagnostics, therapeutics, research & developmental activities and others. Based on end user, the Gene Therapy Technologies Market is classified as academic & research institutes, diagnostics laboratories, biotech & pharmaceutical companies and others.

Request a Sample Copy@ https://www.healthcareintelligencemarkets.com/request_sample.php?id=68930

Key Market Players are:

Biogen (US), Novartis AG (Switzerland), Gilead Sciences, Inc. (US), Spark Therapeutics, Inc. (US), MolMed S.p.A. (Italy), Orchard Therapeutics plc. (UK), SIBIONO (China), Shanghai Sunway Biotech Co., Ltd. (China), bluebird bio, Inc. (US), Human Stem Cells Institute (Russia), AnGes, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics (US), Jazz Pharmaceuticals, Inc. (Ireland), Akcea Therapeutics (US), and Dynavax Technologies (US).

The worldwide geological [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] analysis of the Gene Therapy Technologies Market plan has furthermore been done cautiously in this report. The dynamic establishment of the overall Gene Therapy Technologies Market depends on the assessment of item circulated in various markets, limitations, general benefits made by every association, and future aspirations. The major application areas of Gene Therapy Technologies Market are also covered on the basis of their implementation. The report gives the ideology about different factors and inclinations affecting the development course of the worldwide Gene Therapy Technologies Market. A review of the impact of the administrative regulations and policies on the Gene Therapy Technologies Market operations is also included in this report. The Gene Therapy Technologies Market report offers a complete analysis of competitive dynamics that are modifying and places the patrons ahead of competitors.

Ask for Discount on this Premium Report@ https://www.healthcareintelligencemarkets.com/ask_for_discount.php?id=68930

Reason to Buy

Enquire Before Buying@ https://www.healthcareintelligencemarkets.com/enquiry_before_buying.php?id=68930

Healthcare Intelligence Market:

HealthCare Intelligence Markets Reports provides market intelligence and consulting services to global customers in 145 countries.Being a B2B company, we help businesses respond boldly to evolving market challenges.Create customized syndicated market research reports to help market players build strategies to change games.In addition, reports on the pharmaceutical development, clinical and healthcare IT industries provide future trends and future market prospects.

Contact Us:

Marbella Litt

Phone number: + 44-753-712-1342

Address: 90 State Office Center

90 State Street Suite 700, Albany, NY 12207

sales@healthcareintelligencemarkets.com,

http://www.healthcareintelligencemarkets.com

Read more here:
Covid-19 Update Whats driving the Gene Therapy Technologies Market Growth? See with Prominent Players and High CAGR rate - Bandera County Courier

Recommendation and review posted by Bethany Smith

The Hemophilia Gene Therapy market demand is anticipated to flourish during the forecast period 2020-2027. The report offers information related to import and export, along with the current business chain in the market at the global level. This report provides an in-depth overview of the Hemophilia Gene Therapy market. This includes market characteristics, consisting of segmentation, market share, trends and strategies for this market. The Market Size section provides historical forecasts of market growth and future. An in-depth analysis of the major companies operating in the market is also mentioned in this research report.

The global Hemophilia Gene Therapy market is segmented on the basis of type and application. It also provides market size and forecast estimates from the year 2020 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East & Africa (MEA), and South America (SAM). The Hemophilia Gene Therapy market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of top countries globally along with the current trend and opportunities prevailing in the region.

Receive Sample of Hemophilia Gene Therapy Research Industry @ https://www.coherentmarketinsights.com/insight/request-sample/2480

A thorough examination of the Hemophilia Gene Therapy market includes each and every aspect, which begins with knowing the market, speaking with clients, and evaluating the complete data of the global market. For more clarification, the global market is segmented on the basis of the manufacture of the kind of products, and their applications. The report also delivers information as per the regions based on the geographical classification of the global Hemophilia Gene Therapy market. The dynamic foundation of the global market is based on the calculation of product supply in different markets, their revenues, capability, and a chain of production.

Qualitative information will discuss the key factors driving the restraining the growth of the market, and the possible growth opportunities of the market, regulatory scenario, value chain & supply chain analysis, export & import analysis, attractive investment proposition, and Porters 5 Forces analysis among others will be a part of qualitative information.

Furthermore, this study will help our clients solve the following issues:

All in all, the Hemophilia Gene Therapy market research study elucidates a detailed evaluation of this business and projects this industry to register a commendable growth rate in the forthcoming years. The Hemophilia Gene Therapy market analysis report also delivers important insights with respect to aspects such as the volume of sales, valuation forecast, market size, and the market competition trends as well as the market concentration rate.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2480

Have a look on Key Questions Answered in this Report:

Finally, this business guide will be helpful for both established and new players to sustain in the competitive Hemophilia Gene Therapy market world as it mentions the key geographies, market landscapes alongside the product price, revenue, volume, production, supply, demand, and market growth rate & gives the maximum possible profit for your company.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:[emailprotected]

U.S. Office:Name: Mr. ShahCoherent Market Insights 1001 4th Ave,# 3200 Seattle, WA 98154, U.S.US : +1-206-701-6702UK : +44-020-8133-4027JAPAN : +050-5539-1737LinkedIn | Twitter | Infographics

Know More About Similar Reports: http://bit.ly/Rajkumar123

Follow this link:
Hemophilia Gene Therapy Market- Growth Opportunities by Manufacturers, Regions, Type, Application and Trends Forecast - Cole of Duty

Recommendation and review posted by Bethany Smith

Swiss pharma Novartis AG NVS reported encouraging results for the first quarter of 2020, beating on both sales and earnings. Forward purchasing due to COVID-19 also boosted performance. Moreover, the company maintained its outlook for 2020 even amid uncertainties related to the coronavirus pandemic.

First-quarter 2020 core earnings (excluding one-time charges) of $1.55 per share easily beat the Zacks Consensus Estimate of $1.37 and increased from $1.21 reported in the year-ago quarter.

Revenues rose 11% year over year to $12.3 billion, driven by Entresto, Zolgensma, Cosentyx, Kisqali and Piqray. Revenues beat the Zacks Consensus Estimate of $12.15 billion. Excluding COVID-19-related forward purchases, sales grew approximately 9%.

The stock has lost 5.4% in the year so far against the industrys growth of 0.1%.

All growth rates mentioned below are on a year-over-year basis and at constant exchange rates.

Quarter in Detail

Novartis operates under two segments Innovative Medicines and Sandoz (generics).

The Innovative Medicines division recorded sales of $9.8 billion, up 13% year over year. Within this segment, the Pharmaceuticals business unit grew 14%, driven by continued momentum in Entresto and Cosentyx and the uptake of Zolgensma.

Psoriasis drug, Cosentyx, continues to gain traction. Cosentyx sales increased 19% to $930 million, driven by strong demand in the United States. Entresto sales grew 62% to $569 million, driven by demand growth across geographies. Increasing contribution from Zolgensma (gene therapy for pediatric patients with spinal muscular atrophy) also boosted this business unit.

The Oncology business unit grew 12%, driven by continued momentum in Promacta/Revolade, Tafinlar + Mekinist and Kisqali as well as the launch uptake of Piqray. Kisqali sales surged 82%, driven by strong double-digit growth owing to higher demand in all geographies. Kymriah grew strongly in Europe and the United States.

This growth was partially offset by generic competition for Afinitor, Exjade, Travatan and Exforge.

Sales at the Sandoz division were $2.5 billion, up 11%, driven by volume growth including COVID-19-related forward purchasing, partly offset by price erosion. Biopharmaceuticals sales grew 31%, driven by continued strong double-digit growth in Europe. Novartis has decided to retain Sandoz US generic oral solids and dermatology businesses, after terminating its mutual agreement with Aurobindo.

Guidance for 2020 Reiterated

The company expects net sales in 2020 to grow in mid to high-single digits. Innovative Medicines revenues are projected to grow in mid to high-single digits. Revenues from Sandoz are expected to grow in low-single digits.

COVID-19 Update

The pipeline progress during the quarter was encouraging. Novartis initiated a phase III clinical trial in collaboration with Incyte INCY to evaluate the use of Jakavi in combination with standard of care (SoC) compared to SoC alone for COVID-19 infection and a phase III study on Ilaris in patients with pneumonia as a result of SARS-CoV-2 infection.

Additionally, Novartis announced a phase III study on hydroxychloroquine, alone and in combination with azithromycin, for the treatment of hospitalized patients with COVID-19 disease. Under an expedited managed access program, Novartis has granted requests and provided Jakavi and Ilaris. Requests for investigator-initiated trials have also been granted for COVID-19-related clinical studies of Gleevec, Cosentyx, hydroxychloroquine and Diovan. The company has committed to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.

Story continues

Our Take

Novartis first-quarter results were strong, driven by the solid performance of key drugs like Cosentyx and Entresto, and contribution from gene therapy, Zolgensma. COVID-19 related forward purchasing also boosted performance.

New launches like Piqray and Beovu should further boost the companys performance in the upcoming quarters. In particular, strong uptake is expected from Beovu as it is the first FDA-approved anti-VEGF to offer greater fluid resolution as compared to Regeneron REGN and Bayers BAYRY market-leading drug, Eylea.

Novartis currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportRegeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis ReportIncyte Corporation (INCY) : Free Stock Analysis ReportNovartis AG (NVS) : Free Stock Analysis ReportBayer Aktiengesellschaft (BAYRY) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

More:
Novartis (NVS) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance

Recommendation and review posted by Bethany Smith

Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries Market has provided a comprehensive analysis of the industry. This included the existing market conditions, central or critical regions, the price of the product, capacity, production, demand and supply, profit, growth pace and the outlook. The study has presented recent project SWOT analysis apart from investment feasibility analysis. In turn, a review of the investment return has also been provided to help the stakeholders and any possible new entrants.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries Market: Bluebird Bio, Vical Inc., Sangamo, Avalanche Bio, Celladon, Spark Therapeutics, Dimension Therapeutics, Advantagene and others.

Get Sample Copy of this Report:

https://www.marketinsightsreports.com/reports/04121974871/global-gene-therapy-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/inquiry?Source=heraldwriteup&Mode=48

Segments on the basis of Types are:In Vivo

Ex Vivo

Segments on the basis of Applications:

Cardiovascular Diseases

Infectious Diseases

Monogenic Diseases

Cancer Diseases

Others

Additionally, the report enables a market player not only to plan but also execute lucrative Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries business strategies based on growing market needs by emphasizing leading competitors strategic moves which include recent mergers, ventures, acquisitions, business expansion, product launches, branding, and promotional activities.

Inquire for Discount: SPECIAL OFFER (Avail Up-to 20% discount on this report)

https://www.marketinsightsreports.com/reports/04121974871/global-gene-therapy-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/discount?Source=heraldwriteup&Mode=48

Furthermore, the report encompasses the key strategic developments of the market comprising new product launch, research & development, partnerships, acquisitions & mergers, collaborations & joint ventures agreements, and regional growth of main players in the market on the global and regional basis.

This report provides:

1) An overview of the global market for Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries Market and related technologies.

2) Analyses of global market trends, with data from 2015, estimates for 2020, and projections of compound annual growth rates (CAGRs) through 2027.

3) Identifications of new market opportunities and targeted promotional plans for Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Explore Full Report With Detailed TOC Here:

https://www.marketinsightsreports.com/reports/04121974871/global-gene-therapy-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries?Source=heraldwriteup&Mode=48

The report also tracks the latest market dynamics, such as driving factors, restraining factors, and industry news like mergers, acquisitions, and investments. It provides market size (value and volume), market share, growth rate by types, applications, and combines both qualitative and quantitative methods to make micro and macro forecasts in different regions or countries.

Finally, Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and CountriesMarket report is the believable source for gaining the market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and market development rate and figure and so on. Global Gene Therapy Market Research Report 2015-2027 of Major Types, Applications and Competitive Vendors in Top Regions and Countries industry report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

About Us:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Media Contact Us:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com|irfan@marketinsightsreports.com

See the original post here:
Gene Therapy Market Latest Trends, New Innovation and Global Analysis 2020 to 2027 - Herald Writeup

Recommendation and review posted by Bethany Smith

Worldwide Gene Therapy Market has been thoroughly elaborated in a research report put on sale by Marketresearch.biz, bearing the title Gene Therapy MarketGlobal Industry Analysis, Size, Share, Growth, Trends, and Forecast 20202029. According to the report, the market is expected to be driven by a wide range of macroeconomic and industry-related factors. The key players in this market are focusing on product strategies and developments to increase their customer base and maintain their position.

The Gene Therapy Market is an intrinsic study of the current status of this business vertical and encompasses a brief synopsis about its segmentation. This industry report is inclusive of a nearly accurate prediction of the market scenario over the forecast period 20202029 market size with respect to valuation as sales volume. The study lends focus to the top magnates comprising the competitive landscape of Gene Therapy market, as well as the geographical areas where the industry extends its horizons, in magnanimous detail.

|| Access insightful study with over 100+ pages, list of tables & figures, profiling 10+ companies. Ask for Free Sample Copy(PDF) @https://marketresearch.biz/report/gene-therapy-market/request-sample

Operational and Emerging Players: Gene Therapy Market- Novartis, Kite Pharma Inc, GlaxoSmithKline PLC, Spark Therapeutics Inc, Bluebird bio Inc, Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica PLC, NewLink Genetics Corp., Amgen Inc

According to the current market situation, this report continuously observing promising growth of the global Gene Therapy market. The report further suggests market appears to progress at an accelerating rate over the forecast period. Also, the major players are elaborated on the basis of the proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, report also examines R&D developments, legal policies, SWOT Analysis and strategies of Gene Therapy market players.

This Gene Therapy market research report surrounds importance on:

Manufacturing process and technology used in Gene Therapy market, key developments and trends changing in the development

Complete examination, including an evaluation of the parent market

Detailed account of market, volume and forecast, by leading key players, product type and end users applications

Environmental spread, development designs, pieces of the overall industry, key methodologies, and different financials systems of Gene Therapy market

Industrial analysis by upstream raw materials, downstream industry, current market dynamics and ensuing consumers analysis

|| Place Inquiry for further Details or Customization of Report:https://marketresearch.biz/report/gene-therapy-market/#inquiry

Gene Therapy Market Segmentation Outlook:

By Vector:Viral vectorRetrovirusesLentivirusesAdenovirusesAdeno Associated VirusHerpes Simplex VirusPoxvirusVaccinia VirusNon-viral vectorNaked/Plasmid VectorsGene GunElectroporationLipofection

By Gene Therapy:AntigenCytokineTumor SuppressorSuicideDeficiencyGrowth factorsReceptorsOther

By Application:Oncological DisordersRare DiseasesCardiovascular DiseasesNeurological DisordersInfectious diseaseOther Diseases

Gene Therapy Market Section by Region:

ASIA-PACIFIC MARKET: China, Southeast Asia, India, Japan, Korea, Western Asia

THE MIDDLE EAST & AFRICA MARKET: GCC, North Africa, South Africa

NORTH AMERICA MARKET: United States, Canada, Mexico

EUROPE MARKET: Germany, Netherlands, UK, France, Russia, Spain, Italy, Turkey, Switzerland

SOUTH AMERICA MARKET: Brazil, Argentina, Columbia, Chile, Peru

Our Research Methodology is based on the following main points:

i. Data Collections and Interpretation

ii. Analysis

iii. Data Validation

iv. Final Projections and Conclusion

The latest research on the Gene Therapy Market fundamentally delivers insights that can empower stakeholders, business owners, and field marketing executives to make effective investment decisions driven by facts and extremely thorough research. The study aims to provide an evaluation and deliver essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the Gene Therapy Market for the forecast period, 20202029. To help firms comprehend the Gene Therapy industry in multiple ways, the report exhaustively assesses the share, size, and growth rate of the business worldwide.

There are 13 Sections to show the global Gene Therapy market:

Chapter 1: Market Overview, Drivers, Segmentation overview, Restraints and Opportunities

Chapter 2: Market competition by key Manufacturers

Chapter 3: Production by Regions

Chapter 4: Consumption by Regions

Chapter 5: Production By Types, Revenue and Market share by Types

Chapter 6: Market share (%) and Growth Rate by Applications, Consumption By Applications

Chapter 7: Complete profiling and analysis of leading Manufacturers

Chapter 8: Region-wise manufacturing expenses, Manufacturing cost analysis, Raw materials analysis

Chapter 9: Sourcing Strategy, Industrial Chain and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Effect Factors Analysis, Impact Analysis

Chapter 12: Market Forecast 2020-2029

Chapter 13: Gene Therapy Research Findings and Conclusion, methodology and data source, Appendix

CLICK HERE, To Get Complete TOC

Conclusively, this report will provide you a clean view of each and every truth of the market without a need to consult another research report or a statistics supply. Our report will offer you with all of the facts about the past, present, and future of the Market.

Contact Us At

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:[emailprotected]

Continued here:
Inclusive Comprehension 2020: Gene Therapy Market (Trending PDF) Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - Jewish Life...

Recommendation and review posted by Bethany Smith

In times of crisis, top quality management is more important than ever. There is no script to follow and few parallels to draw from history for these unprecedented times. So now more than ever it is important to have companies in the portfolio which not only have sound business models but also have exceptional management teams. CSL is one such company.

Despite the amazing run the share price has had, CSL remains a solid long term investment proposition. It operates in a global growing industry and occupies a strong position within it. It is well managed, earns a high return on capital due to its numerous competitive advantages and has plenty of opportunities to reinvest which should drive growth for many years to come.

Whilst not excessively cheap based on near term earnings, high-quality companies like CSL have the propensity to surprise on the upside - time and time again.

Two-year chart of the CSL share price

How is CSL navigating COVID-19?

CSL provides lifesaving and largely non-discretionary treatments to seriously ill patients as well as manufacturing the seasonal flu vaccine. The current pandemic has seen increased demand for CSLs core IVIG products and flu vaccine. It is a credit to CSLs execution it has been able to maintain consistent supply to all countries, despite country lockdowns and border closures.

However, CSL is not completely immune to some temporary disruption and is currently experiencing a reduction in collected plasma volumes as fewer people visit collection centres and stay home. The impact of this wont be seen for another 6-9 months due to CSLs long manufacturing cycle, which provides it with time to work on mitigation strategies to reduce the impact.

In the US donors are paid to give plasma so donation tends to increase in times of high unemployment. As a result, it is likely CSL will see a particularly strong rebound in collected plasma as social distancing measures are relaxed. This will help offset the reduction being experienced right now and may well see CSL gain further market share as it has invested more heavily in its collection network than other fractionators.

CSL is also responding to COVID-19 from 3 different angles:

These will be ongoing studies, none of which is expected to impact earnings in the short term, but may provide longer-term opportunities.

CSL is exceptionally well managed and has earned a reputation of focussing on patients, investing in its staff, being a reliable supplier of lifesaving products and a consistent executor of a sound business strategy.

It occupies a strong position within its industry and has built up numerous sustainable competitive advantages that have allowed it to consistently earn a high return on invested capital, which should drive shareholder value for many years to come.

The global plasma product market is growing at a healthy 8-10% pa and demand is outstripping supply. Demand for key products such as IG (Immunoglobulins) is being driven by increased diagnosis and awareness of conditions that benefit from IG treatment and supply is constrained due to the fact that CSL has been the only plasma fractionator that has continued to invest and open plasma collection centres over the past decade.

Opening a plasma collection centre requires both financial investment and time time to get the centre approved and time to draw in sufficient donors to collect enough plasma for the centre to reach scale. CSL had the foresight to continue investing in these centres while its competitors stopped, resulting in today having access to much more raw material (plasma) than its competitors. This has allowed it to gain market share and importantly, consistently supply its lifesaving treatments to patients.

CSL has also continuously invested in best in class manufacturing facilities. The amount of capital required to reach scale and meet the regulatory requirements of plasma fractionation is in itself a barrier to new entrants to this industry.

CSLs efficiency in manufacturing enables it to extract more product and value per litre of plasma than its competitors, making CSL the lowest cost producer. This results in a higher profit margin and boosts its ability to invest in R&D for new products and therapies.

Reinvest for long term growth

As mentioned, CSL reinvests a healthy chunk of cashflow back into R&D projects and history demonstrates a high hit rate in successfully commercialising this a return on investment of over 25%. This goes not only to the talent of the researchers working on the science of each project, but also to CSLs ability to select projects that have the most promise and the grit to shut a project down if its unlikely to stack up commercially.

New product launches to treat a variety of rare diseases as well as improvements on existing therapies have been an important driver of CSLs profitability. There is a strong pipeline of R&D projects addressing unmet clinical needs. Not all will be successful and these opportunities are impossible to accurately value, but using track record as a guide, there are enough long dated opportunities in the pipeline to underpin good long-term growth.

Good stewards of shareholder capital

As well as managing the operational aspects of the business exceptionally well, CSL management along with the board, also have an excellent track record of being good stewards of shareholder capital. CSLs business is by nature highly capital intensive, however it has still been able to achieve a return on invested capital of well in excess of 20% consistently for many years.

CSL is a good example of how linking management long term incentives to return on capital (which not enough companies do) can benefit shareholders over the long term. This has resulted in CSL investing back in the business where the return justifies the capital and at times over the years, returning excess capital to shareholders.

Rival therapies?

The nature of biotechnology is that there will always be competing new products and new breakthroughs that may threaten current products. This is why continuing to invest in R&D is so important. There are various therapies in early stages that may threaten or at least change the demand curve for CSLs products - two often mentioned are gene therapy and FcRn inhibitors.

Both are still in early trial phases and even if successful, the adoption profiles are unknown. It is worth noting that CSL is involved in its own research into these potentially competing therapies, for example acquiring gene therapy company Calimmune, demonstrating a willingness to disrupt itself if necessary.

CSL remains an attractive long-term investment opportunity

COVID-19 has not changed CSLs expected FY20 earnings. Guidance was recently affirmed by the company, however, FY21 presents both challenges and opportunities. Challenges regarding plasma collection volumes and opportunities regarding increased demand for the flu vaccine. The pandemic is likely to raise awareness of the flu vaccine and create a higher level of demand for it. Also, there is the potential to manufacture treatments and/or a vaccine for COVID-19 in the future.

Unlike many other companies through this crisis, CSL does not need to raise capital. Its balance sheet is solid and it has access to a further $1bn in liquidity if necessary.

CSLs share price has outperformed the market in the recent sell off but is off its highs in absolute terms. Like many healthcare companies at the moment its headline PE is higher than its historic average but using valuation methods which take into account the duration of CSLs growth prospects and current low interest rates as well as the current market and economic uncertainty, CSL remains an attractive long term investment opportunity.

We believe long term value creation is achieved by going deeper into company analysis, balanced with the rigour of an objective process. We provide investors with access to risk controlled, active equity returns through a unique investment process that combines quantitative analysis with deep fundamental research. To find out more visit our website, or click contact below.

Read more here:
CSL still a solid long-term proposition - Kelli Meagher - Livewire Markets

Recommendation and review posted by Bethany Smith

The research study on Global Personalized Gene Therapy Treatment market 2019 presents an extensive analysis of current Personalized Gene Therapy Treatment market size, drivers, trends, opportunities, challenges, as well as key Personalized Gene Therapy Treatment market segments. Further, it explains various definitions and classification of the Personalized Gene Therapy Treatment industry, applications, and chain structure.In continuation of this data, the Personalized Gene Therapy Treatment report covers various marketing strategies followed by key players and distributors. Also explains Personalized Gene Therapy Treatment marketing channels, potential buyers and development history. The intent of global Personalized Gene Therapy Treatment research report is to depict the information to the user regarding Personalized Gene Therapy Treatment market forecast and dynamics for the upcoming years. The Personalized Gene Therapy Treatment study lists the essential elements which influence the growth of Personalized Gene Therapy Treatment industry. Long-term evaluation of the worldwide Personalized Gene Therapy Treatment market share from diverse countries and regions is roofed within the Personalized Gene Therapy Treatment report. Additionally, includes Personalized Gene Therapy Treatment type wise and application wise consumption figures.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

After the basic information, the global Personalized Gene Therapy Treatment Market study sheds light on the Personalized Gene Therapy Treatment technological evolution, tie-ups, acquisition, innovative Personalized Gene Therapy Treatment business approach, new launches and Personalized Gene Therapy Treatment revenue. In addition, the Personalized Gene Therapy Treatment industry growth in distinct regions and Personalized Gene Therapy Treatment R;D status are enclosed within the report.The Personalized Gene Therapy Treatment study also incorporates new investment feasibility analysis of Personalized Gene Therapy Treatment. Together with strategically analyzing the key micro markets, the report also focuses on industry-specific drivers, restraints, opportunities, and challenges in the Personalized Gene Therapy Treatment market.

Global Personalized Gene Therapy Treatment Market Segmentation 2019: Personalized Gene Therapy TreatmentThe study also classifies the entire Personalized Gene Therapy Treatment market on basis of leading manufacturers, different types, various applications and diverse geographical regions. Overall Personalized Gene Therapy Treatment market is characterized by the existence of well-known global and regional Personalized Gene Therapy Treatment vendors. These established Personalized Gene Therapy Treatment players have huge essential resources and funds for Personalized Gene Therapy Treatment research as well as developmental activities. Also, the Personalized Gene Therapy Treatment manufacturers focusing on the development of new Personalized Gene Therapy Treatment technologies and feedstock. In fact, this will enhance the competitive scenario of the Personalized Gene Therapy Treatment industry.

The Leading Players involved in global Personalized Gene Therapy Treatment market are:

By Therapy (Targeted Treatments and Pharmacogenomics),By Application (Breast Cancer, Brain Cancer, Colorectal Cancer, Certain Childhood Cancers, Gastrointestinal Stromal Tumor, Kidney Cancer, Leukemia, Lymphoma, Melanoma, Lung Cancer, and Multiple Myeloma)By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10225585

Worldwide Personalized Gene Therapy Treatment Market Different Analysis:Competitors Review of Personalized Gene Therapy Treatment Market: Report presents the competitive landscape scenario seen among top Personalized Gene Therapy Treatment players, their company profile, revenue, sales, business tactics and forecast Personalized Gene Therapy Treatment industry situations. Production Review of Personalized Gene Therapy Treatment Market: It illustrates the production volume, capacity with respect to major Personalized Gene Therapy Treatment regions, application, type, and the price. Sales Margin and Revenue Accumulation Review of Personalized Gene Therapy Treatment Market: Eventually explains sales margin and revenue accumulation based on key regions, price, revenue, and Personalized Gene Therapy Treatment target consumer. Supply and Demand Review of Personalized Gene Therapy Treatment Market: Coupled with sales margin, the report depicts the supply and demand seen in major regions, among key players and for every Personalized Gene Therapy Treatment product type. Also interprets the Personalized Gene Therapy Treatment import/export scenario. Other key reviews of Personalized Gene Therapy Treatment Market: Apart from the above information, correspondingly covers the company website, number of employees, contact details of major Personalized Gene Therapy Treatment players, potential consumers and suppliers. Also, the strengths, opportunities, Personalized Gene Therapy Treatment market driving forces and market restraints are studied in this report.

Highlights of Global Personalized Gene Therapy Treatment Market Report:* This report provides in detail analysis of the Personalized Gene Therapy Treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2019 ; 2029. * It also elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for world Personalized Gene Therapy Treatment market. * This study also provides key insights about Personalized Gene Therapy Treatment market drivers, restraints, opportunities, new product launches, approvals, regional outlook, and competitive strategies adopted by the leading Personalized Gene Therapy Treatment players. * It profiles leading players in the worldwide Personalized Gene Therapy Treatment market based on the following parameters ; company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans. * Insights from Personalized Gene Therapy Treatment report would allow marketers and management authorities of companies to make an informed decision with respect to their future product launches, market expansion, and Personalized Gene Therapy Treatment marketing tactics. * The world Personalized Gene Therapy Treatment industry report caters to various stakeholders in Personalized Gene Therapy Treatment market. That includes investors, device manufacturers, distributors and suppliers for Personalized Gene Therapy Treatment equipment. Especially incorporates government organizations, Personalized Gene Therapy Treatment research and consulting firms, new entrants, and financial analysts. *Various strategy matrices used in analyzing the Personalized Gene Therapy Treatment market would provide stakeholders vital inputs to make strategic decisions accordingly.

Global Personalized Gene Therapy Treatment Market Report Provides Comprehensive Analysis of Following: ; Personalized Gene Therapy Treatment Market segments and sub-segments ; Industry size ; Personalized Gene Therapy Treatment shares ; Personalized Gene Therapy Treatment Market trends and dynamics ; Market Drivers and Personalized Gene Therapy Treatment Opportunities ; Supply and demand of world Personalized Gene Therapy Treatment industry ; Technological inventions in Personalized Gene Therapy Treatment trade ; Personalized Gene Therapy Treatment Marketing Channel Development Trend ; Global Personalized Gene Therapy Treatment Industry Positioning ; Pricing and Brand Strategy ; Distributors/Traders List enclosed in Positioning Personalized Gene Therapy Treatment Market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10225585

Moreover, the report organizes to provide essential information on current and future Personalized Gene Therapy Treatment market movements, organizational needs and Personalized Gene Therapy Treatment industrial innovations. Additionally, the complete Personalized Gene Therapy Treatment report helps the new aspirants to inspect the forthcoming opportunities in the Personalized Gene Therapy Treatment industry. Investors will get a clear idea of the dominant Personalized Gene Therapy Treatment players and their future forecasts.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth ResearchEmail: [emailprotected]Phone: +1 313 462 0609

See the rest here:
Personalized Gene Therapy Treatment Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2029 - Germany English...

Recommendation and review posted by Bethany Smith

The comprehensive report titled Global Gene Therapy for Mucopolysaccharidosis Market 2020 by Manufacturers, Countries, Type and Application, Forecast to 2025 was published by MarketsandResearch.biz to understand the complete setup of market industries. The report evaluates the market growth rate and the industry value on the basis of growth-inducing factors, market dynamics, and other related data. The report focuses on the size and framework of the global Gene Therapy for Mucopolysaccharidosis market to present the understanding of the existing structure of the market. The report has collected the latest industry news, trends, as well as opportunities. The document comprises a complete market analysis and provider landscape with the help of a SWOT analysis of the major service providers.

Market Outline:

This research report is helpful for both established businesses as well as startups in the market. Furthermore, the research is ideally and characteristically punctuated with the illustrative presentation. The study offers a detailed investigation of the historical records, current statistics, and future predictions from 2020 to 2025. Challenges faced by the industries and approaches adopted by them to overcome those threats have been identified. Moreover, it offers a complete analysis of the market size, segmentation, and market share as well as market dynamics such as market restrains, growth drivers, opportunities, service providers, stakeholders, investors, key market players, profile assessment, the global Gene Therapy for Mucopolysaccharidosis market. The global market report is designed through detailed qualitative insights, verifiable projections, and historical data about the global market size.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/9426

The company profile section of the report offers great insights such as market revenue and market share of the global Gene Therapy for Mucopolysaccharidosis market. Key companies listed in the report are: Sangamo Therapeutics, Swedish Orphan Biovitrum, uniQure,

Segment based on type: Intravenous, ICV, Intracerebral, Intracisternal

Segment based on application: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III A, Mucopolysaccharidosis III B,

Regional Segments:

The section on regional segmentation describes the regional aspects of the global Gene Therapy for Mucopolysaccharidosis market. This part of the report explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market. Region Included: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/9426/global-gene-therapy-for-mucopolysaccharidosis-market-2020-by-manufacturers-countries-type-and-application-forecast-to-2025

The Market Report Can Answer The Following Questions:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

View original post here:
Global Gene Therapy for Mucopolysaccharidosis Market 2020 Overview, Top Companies, Region, Application and Forecast by 2025 - NJ MMA News

Recommendation and review posted by Bethany Smith

Plasmid DNA Manufacturing Market research report is the professional study with the premium insights which includes the size of the business, the ongoing patterns, drivers, dangers, conceivable outcomes and primary segments. The report encompasses the competition landscape entailing share analysis of the key players in the Plasmid DNA Manufacturing market based on their revenues and other significant factors. Report analyzes changing trends and competitive analysis which becomes essential to monitor performance and make critical decisions for growth and development. It also provides market information in terms of development and its capacities.

Get Sample Copy of this report @: https://www.a2zmarketresearch.com/sample?reportId=231682

Leading companies Influencing in this Market are:

Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy Catapult, VGXI, PlasmidFactory, Kaneka Corporation, Nature Technology Corporation, Waisman Biomanufacturing, FUJIFILM Diosynth Biotechnologies, LakePharma.

In this Plasmid DNA Manufacturing Market research report, the prominent factors driving the advancement of this market were recorded and the business accomplices and end administrators were indulgent. The setup of the business division, examples, and challenges monitoring the market comprehensively are in like manner a bit of this wide examination. Different meetings and social events were driven by the distinguishable pioneers of this industry to get persisting and revived encounters concerned to the market.

The report gathers the essential information including the new strategies for growth of the industry and the potential players of the global Plasmid DNA Manufacturing Market. It enlists the topmost industry player dominating the market along with their contribution to the global market. The report also demonstrates the data in the form of graphs, tables, and figures along with the contacts details and sales of key market players in the global Plasmid DNA Manufacturing Market.

Global Plasmid DNA Manufacturing Market Segmentation:

Segmentation by Type:

HQ Grade Plasmid DNAGMP Grade Plasmid DNANon-GMP Grade Plasmid DNA

Segmentation by Application:

CancersInherited DisordersViral InfectionsOthers

Buy Exclusive Report @: https://www.a2zmarketresearch.com/buy?reportId=231682

Key questions answered in the report include:

Table of Contents

Global Plasmid DNA Manufacturing Market Research Report 2020 2026

Chapter 1 Plasmid DNA Manufacturing Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Plasmid DNA Manufacturing Market Forecast

For more Information! Ask to Experts @: https://www.a2zmarketresearch.com/enquiry?reportId=231682

If you have any special requirements, please let us know and we will offer you the report as you want.

Read the original:
Future Prospects of Plasmid DNA Manufacturing Market by 2026 with Top Key Players Cobra Bio, Richter-Helm, Eurogentec, Cell and Gene Therapy...

Recommendation and review posted by Bethany Smith

The coronavirus pandemic has triggered a race for disruptive innovation in diagnostics, new therapies and novel vaccines, but the global life sciences industry was already expected to reach more than $2 trillion in gross value by 2023, up from $1.6 trillion before the crisis.

The pharmaceutical sector has long been attractive for family office investors, either directly or as part of their diversified portfolio. More than a quarter (27%) of families surveyed by Campden Wealth with UBS for The Global Family Office Report 2019 said they directly invested in health care and social assistance. It was the fourth most popular sector for families behind technology (49%), real estate and rental/leasing (42%) and finance and insurance (30%).

Dr Annalisa Jenkins MBBS, MRCP is a life sciences thought leader with more than 25 years of biopharmaceutical industry experience. The former surgeon lieutenant commander in the British Royal Navy during the Gulf Warsaid new entrepreneurial healthcare and biotech investment opportunities were opening for family investors from the disruptive revolutions in technology, stem cell therapy and mental health.

In an interview held before the coronavirus outbreak, the Chair of the Court of the London School of Hygiene and Tropical Medicine at the University of London, and chair or board member of Cellmedica, Vium and Cocoon Biotech, among others, tells CampdenFB which areas of investment she is personally interested in, the innovative trends she is seeing and what family investors need to know before entering the sector.

What is your outlook for investments in 2020?

Im hugely optimistic moving into the next decade. Whilst I think that one can always recognise that the geopolitical environment that we now operate in has markedly evolved in the last few years, whether that be the notion of risk, uncertainty, unpredictability, theres no doubt that has significantly evolved. Some of the driving factors behind that include global leadership, the climate evolution were living through, but ultimately the world of investment and the opportunities continue to be exciting.

When one looks across the field of health and innovation, were living in the so-called Fourth Industrial Revolution, and there is probably no sector that exemplarises that more than the health tech and life science sector. Today I would say the innovation coming out of our academic universities is as broad and as advanced as I have seen in the last 30 years of my career. I think the ability to access capital is just remarkable on a global basis, there are trillions of dollars that are out there in different parts of the economy, looking for innovation and looking for leaders to invest in. And, of course, we have a technology revolution that is ongoing, particularly driven by our ability to generate, curate and process data and deliver insights which are going to transform how we access and deliver healthcare and think about keeping people on a global basis well and healthy for longer and deliver improved therapeutics to reduce suffering.

I dont think I could be really more optimistic entering this new decade when it comes to thinking about the combination of equity with innovation and disruption and the evolution of the world I operate in.

What are the headwinds for investments in healthcare and life science?

The biggest concerns are around the well-publicised debates on pricing of technologies, particularly in the US, and how to ensure every individual can get equal access to health. Those two areas will continue to be debated and drive short-term cyclical uncertainty. There is no doubt global leadership, and that includes the US, recognise that for stable societies, access to universal healthcare and the ability of populations to be happy, healthy and flourishing lies as the centre of their political ambition.

Which healthcare investments are you excited about?

The cross-cutting themes that I am particularly excited about when it comes to technology are the ability for machine-learning and AI [artificial intelligence] to generate algorithms and therefore products that can be placed into the hands of individuals for them to manage, track and improve their health.

For example, there are products coming along in the area of mental health and wellness where individuals increasingly in the future will be able to access through their mobiles programmes and support services which will help them track their mood and maintain their wellness. We know that many diseases, for example, of the gastrointestinal system like irritable bowel syndrome, are markedly impacted by mental health and wellbeing. Interventions such as digital therapeutics, such as apps that are regulated and provided as therapeutics, are set to transform the way these diseases are managed. I am consistently looking for technologies that can be placed into the hands of individuals for self-directed and personalised prevention and care management.

Secondly, the ability of technology to improve the way we plan and conduct research and development on a global basis truly again going to be disrupted in the future by our ability to get large datasets in an ethical way to translate that into pre-clinical discoveries of new therapeutics. And then in the clinical setting to conduct novel clinical trials and to really change the way we bring new therapies to market, like new therapeutics, medical devices, diagnostics, biochemical markers across the board, so I am very interested in companies that are pursuing that.

Thirdly, the area of how do we optimise healthcare utilisation, the efficiency and the effectiveness, whether that be here in the UK in the NHS [National Health Service] or globally. Its absolutely clear that if we want to ensure affordable access to the top quality healthcare and outcomes for populations, were going to need embrace digital innovations, so companies that operate in that space are very attractive.

Those are the cross-cutting themes. If I look at the verticals, I would say to you, of course, there are very good investments to be made in the area of cancer and oncology. However, there is a marked amount of money in that space, its a little bit overpopulated. So for family offices and alternate sources of capital I would not be placing my money there at this point. I would be looking at counter cyclical trends, so areas that are perhaps now emerging. Areas such as womens health, otherwise known as Femtech, clearly now emerging as an area for investment and has been systematically underinvested in over the last 10-15 years. Cardiovascular disease continues to be the biggest killer and cause of illness on a global basis and yet it really hasnt received a lot of attention in investment. Were now seeing a wave of innovations and were starting to see more about the biology of heart disease, stroke and diabetes so again I would see that as an area of interest [as is] stem cells in therapeutics across a whole spectrum of diseases. Im particularly interested in Type 1 diabetes and the ability to generate beta cells for the production of insulin in patients with Type 1 diabetes. We are starting to see companies emerging and exploring that space so really stem cells and the cell therapy space, along with gene therapy is very interesting.

For family offices, the whole area of mental health and wellness is enormous and growing. The reason is its now becoming apparent people are talking about mental health and wellness in a way thats reducing stigma and then allowing money to flow into this space. How we deal with the human brain and preserving the health and wellness of the brain, both from an emotional and physical point of view, whether that be the prevention of degenerative brain disorders like dementia or the management of anxiety and all the related diseases known as depression, is a very interesting space for investment and its where I am investing in a lot.

How can family offices enter and succeed in the healthcare and biotech investment market?

Its extremely difficult as a family office to make an initial move into the sector, largely because its extremely complicated and it really rather depends on what the investment goals are and the returns that are desired. The sector is highly fragmented and family offices have traditionally and largely invested in the more sustainable, long-term world of pharma as part of a general equity portfolio. Were talking about a very different sector which is largely based on entrepreneurship, a lot of risk and deep science, so I think the first thing to say is that family offices, before moving into or when in this space, should ensure they have the access to the right expertise around the table. They can gain that either through their own networks of advisers or by participating through investments in a fund.

Often the best way to get started is to find a fund that meets the investment criteria of a family office and to start to invest through that. Not through a traditional VC fund, there are number of funds coming together with the sole purpose of accessing family offices, sovereign wealth funds, alternate sources of capital and then investing through that because its really important in the risky healthcare and life science sector to have a portfolio view that is very strategically put together. You have to be prepared to fail and to be prepared to be a long-term patient investor thats willing to along five-to-seven years for the ride.

Read more:
Dr Annalisa Jenkins on healthcare and biotech investments for family offices - Campden FB

Recommendation and review posted by Bethany Smith

Bluebird Bio

Global Gene Therapy For CNS Disorders Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=175792&utm_source=LHN&utm_medium=888

Gene Therapy For CNS Disorders Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Gene Therapy For CNS Disorders industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Gene Therapy For CNS Disorders industry.

-> Furthermore, we will help you to identify any crucial trends to predict Gene Therapy For CNS Disorders market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Gene Therapy For CNS Disorders market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=175792&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Gene Therapy For CNS Disorders market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Gene Therapy For CNS Disorders market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Gene Therapy For CNS Disorders Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Gene Therapy For CNS Disorders Market Size, Gene Therapy For CNS Disorders Market Growth, Gene Therapy For CNS Disorders Market Forecast, Gene Therapy For CNS Disorders Market Analysis

Our Trending Reports

U.S. Pest Control Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Battery Monitoring System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Link:
Gene Therapy For CNS Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Recommendation and review posted by Bethany Smith

Stem Cell Restore is a formula that works toward improving your health on a cellular level to decrease age-related weakness and fatigue. This product employs natural ingredients for reaching its goals such as resveratrol, black current cocktail, icariin, and grape seed.

Multiple research works from renowned universities back the approach that this product takes. The best part is that it makes you feel stronger, younger, more refreshed, and more energetic without requiring you to get injected with needles. A simple and convenient solution. Another anti-aging plus weight loss supplement that you can opt for is Resurge. This is a new formula by John Barban. Interested folks can learn more about Resurge customer reviews on USAToday.

Stem Cell Restore Review

Aging is the only thing in your life that is bound to happen. Unfortunately, it is not the best experience. Sure, it gives you wisdom, but those wrinkles, that weakness, declining energy levels all these negative factors completely loot the good things. After all, no one likes to wake up in the morning to feel down and weak. No one likes it when it their joints ache or when they look in the mirror to see a dull reflection.

This brings us to possible solutions that you can go for. One of these is Stem Cell Restore. This is a potent dietary supplement that has been made using natural ingredients. The product is backed by science which is what marks it as reliable. Since it comes in the form of capsules, it can be a convenient addition to your routine. Hence, if you are on the lookout for an age-reversing formula, this is one that you can invest in.

Why Choose This Product?

Around the globe, women and men alike are waiting for a magical solution for saving themselves from accelerated aging. There certainly are many options available out there. However, most of these are not worth it. Why? Because they come with negative side effects. Not to mention, these so-called techniques for erasing the effects of aging are all supremely painful. They involve countless injections or an elaborate surgery.

Would you like to still go for these youth preserving tactics? Surely, youre at the very least hesitant. If you decide to go ahead nevertheless, know that the procedures are expensive. They cost hundreds of dollars and still, they are unnatural and eventually make your skin sag. This is where Stem Cell Restore comes into the picture and steals the limelight. The dietary supplement is based on the concept of stem cell surgery.

However, it has three favorable points that win over any surgery. First of all, it doesnt cost as much. In fact, you get to become youthful, energetic, and strong all with a solution that is less than $100. Secondly, the product happens to be completely natural. It doesnt contain any harmful components such as chemicals, additives, preservatives, and the like. This translates to safe usage. Lastly, theres no needles involved; you are just supposed to take the pills regularly.

Working Of This Product

Stem Cell Restore taps into the idea of repairing cells and rejuvenating them. By doing so, it is able to refresh your health completely. All your parts from tendons and joints to your heart and kidneys are able to function better as a result. Old cells are repaired at a fast rate and new ones are created. This makes you feel fresher, and more active. Its not uncommon of people to experience bodily aches and fatigue after crossing 30 years of age.

This product is a suitable solution for everyone. It gets to the core of preserving youth and improves health. Moreover, it also tackles the issue of inflammation which is what disturbs health in numerous ways. Unlike mainstream products, your skin is not the only organ that benefits. In fact, your entire body experiences the effects. To reach its goals, the formula employs only natural ingredients which are effective at their job. As mentioned above, Resurge is another formula for deep sleep and anti-aging. It comes with a money-back guarantee. You can check out more Resurge reviews on Yahoo Finance before deciding which one to buy among the two.

Ingredients Of This Product

Stem Cell Restore has an entirely natural composition. It doesnt comprise of any such ingredients which can have damaging effects in the short- or long-run. The product is a winner mainly because of this. No additives, fillers or other such harmful components are present in the formula. Since all the ingredients are completely organic you dont have to worry about any negative side effects of use. Lets take a look at the ingredients:

Pricing Of The Product

Did you know that you can get this product for absolutely free? Yes, thats true. For a trial period, the dietary supplement is entirely free of cost. You just have to pay for shipping and handling which just requires $9.95 from your wallet. The trail period lasts for 30 days.

If the product satisfies you, its yours and automatically charges are deducted from your account or card. Thats simple and gives you a chance to see whether or not this supplement actually works. There are also three bonus products that tag along with this supplement. These come for free as well. Heres a list of the bonus product that accompany:

Verdict

Stem Cell Restore is a great product for maintaining youthful energy and strength. The product is great for recovering from the pain and fatigue that usually occurs after the age of 30. This formula repairs and encourages the production of cells through the body. In this way, it improves each organs functionality and hence, overall health. You can know more about this dietary supplement by visiting its website online.

Related

Continue reading here:
Stem Cell Restore Helps Regain Youthful Strength And Energy - ZOBUZ - Zobuz

Recommendation and review posted by Bethany Smith

The coronavirus crisis is affecting every aspect of our lives, including the condition of our skin. Have you noticed that your skin is particularly spotty, irritated and angry lately? That's another thing you can blame on COVID-19.

Express.co.ukspoke to Dr. Luca Russo, Dermatologist at Urban Retreat, to find out why.Dr. Russo says there are several reasons for your unexpected breakouts.He said: "There might be several reasons for noticing a tendency to break out during this national emergency."It's probably to do with what's going on inside, and what you're putting in your body, says Dr. Russo.

READ MORE- Coronavirus symptoms: Man reveals skin-related warning sign

Are you up all night worrying about the virus?Dr. Russo says: "The most likely cause of your breakout is stress."During such uncertain and stressful times, our system copes with increased production of Cortisol."Cortisol is an androgen hormone that is released when we are facing unusual challenges and prepare us to "fight'."However, it will also increase the sugar level in the bloodstream and production of sebum that might be a cause of the breakout."

In order to prevent breakouts that stem from high levels of stress, you'll need to calm yourself down.Dr Russo recommends doing activities that allow you to relax and unwind, such as yoga.He also suggests exercising regularly, so it's time to start making use of that daily government-approved walk, cycle, or run.

If you hate exercising, don't worry, the antidote to high cortisol levels doesn't have to be physical.Laughing, a solid night of sleep, or practising your favourite hobby are all effective options.

Having a soak in the bath and doing a face-mask may help you feel more in control of your skin.

This relief may cause a decrease in oil production and pimples.

DON'T MISS...How to help your brain through the coronavirus crisis stress [EXPLAINER]Coronavirus: How to look after your mental health during lockdown [EXPLAINER]Lockdown exercise: The eight exercises you can do at home [INFORMER]

Can you honestly say you have been eating well throughout the lockdown?Most people have stocked up on sugary treats and salty snacks in order to cheer themselves up in the face of COVID-19.And what about the good-old "support local businesses" excuse you use every time you order a greasy takeaway?Dr Russo says: "During isolation food becomes one of the few focal points of the day with more consumption of comfort food."Just like any other organ in your body, a poor diet affects your skin negatively.The body breaks down our food into tiny particles of proteins, fats, and carbs, and circulates it to the organs that need them.These nutrients make their way to your skin too, impacting its condition.It makes sense that inflammatory foods, such as sweets, some dairy, processed meat, and refined carbohydrates, will cause a flare-up in your complexion.

Dr. Russo says: "To improve your skin, you must eat well."Eat foods that are packed with vitamins and proteins and snack on fruit and veg."Drinking lots of water will replace the moisture that is lost through sweat and other processes, keeping your skin hydrated.If you fill up on foods rich in healthy oils and omega-3 fatty acids, you will improve the collagen production in your skin.This makes your skin smoother, suppler, and will help you in the longterm by preventing premature ageing.These oils and fats are found in fish, nuts, olive oil, and many more commonly found items.

During the lockdown, we're stuck inside all day and often don't get a chance to let our skin feel the sun.Dr. Russo says: "At the moment, skin isn't being exposed to natural light much at all."When your skin is exposed to natural light, the production of Vitamin D is increased."Endorphins are also produced, and this boosts your immune system and well-being."Make sure you get some fresh air every day, in order to reap these benefits of the sun.The sun is a great natural resource to improve your skin, but make sure you protect yourself with sun protection before you go out.You should wear an SPF of at least 30 on your face whenever you leave the house or are in front of a window for a prolonged amount of time.

Most people are shunning makeup in favour of the natural look since no one other than our household is going to see our faces.This means you may be tempted to skip your cleansing routine and go straight to bed once the day is over.

If you normally get facials and now can't, this may also be why you are breaking out or seeing changes.Dr. Russo explains: "You have probably been unable to receive professional treatments over this time, and this will contribute towards your breakouts."Dr. Russo recommends continuing with your normal skincare routine.He says: "Carry on as normal, but add an exfoliating cleanser to your routine."Exfoliating cleansers make your skincare routine shorter, by combining exfoliating and cleansing in one step.They remove dead skin cells and any build-up of dirt and oil in one go.There are hundreds of physical exfoliating cleansers on the market, as well as chemical exfoliating cleansers, so take your pick!

While surgical masks are thought to protect us against coronavirus, they're not great for our skin, said Dr. Russo.Wearing a mask over your face for many hours is damaging to your skin, especially when it's hot outside.The mask offers the perfect spot for bacteria and germs to harbour.Try double cleansing on the lower half of your face if you've worn a surgical mask for a prolonged period of time.

More here:
Breakouts: Why is my skin worse during the coronavirus pandemic? - Express

Recommendation and review posted by Bethany Smith

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

New Protein IDed that May Cause Alzheimers

Scientists at the University of Tokyo tested 19,151 individual genes looking for their effect on amyloid beta levels. Amyloid beta is one of the proteins that accumulates in the brains of Alzheimers patients and is generally viewed as one of the primary drivers of the disease. They identified a new protein using CRISPR/Cas9 gene editing, called calcium and integrin-binding protein 1 (CIB1). They found that cells without functional CIB1 genes generate abnormally high levels of amyloid beta protein. The research was published in FASEB Journal.

We believe this is the first time anyone has used this CRISPR/Cas9 genetic screening technique to look for changes in amyloid beta production, said Yukiko Hori, co-first author and lecturer at the University of Tokyo.

In normal, healthy cells, CIB1 is not directly involved with processing amyloid beta, but it stays attached to another protein, gamma secretase inside cells and at the cell membrane. In cells that dont have CIB1, gamma secretase stays inside the cell longer and doesnt leave the membrane. Amyloid beta undergoes multiple steps before reaching its final form. Normally, gamma secretase processes amyloid beta precursors to help produce the final amyloid beta protein. This happens inside the cell, then gamma secretase moves to the cells outer surface membrane.

Patients diagnosed with early-stage Alzheimers disease have lower levels of CIB1 in their brains, while people with late-stage Alzheimers have higher-than-healthy levels of CIB1.

We cannot say for certain why CIB1 is increased in late-stage Alzheimers disease, said Taisuke Tomita, who runs the research lab where the study was conducted. What is important is that in both the early and late stages of Alzheimers disease, something is abnormal about the regulation of CIB1.

Possible Approach to Improving Gene Therapy

Investigators at the University of Groningen have developed a technique that may improve gene therapies. They use DNA/lipid complexes (lipoplexes). Because the viruses used traditionally in gene therapies can cause an immune response and the cells endosomes tend to degrade DNA or other particles, the lipoplex provides protection. They can fuse with the endosome membrane, which prevents degradation.

Gene Promoters that Can Be Used to Treat Neurological Diseases

Researchers at Princeton Neuroscience Institute have developed new gene promoters that act like switches to turn on gene expression. They can be used in gene therapy, with a particular interest in neurological diseases such as Parkinsons and Alzheimers. Viruses are used to carry genes into cells during gene therapy, typically adeno-associated viruses. The Princeton team used promoters found in herpes viruses, which take up less space than existing promoters and allow the transport of larger genes or multiple genes. They are also long-lasting.

Biosensor to Detect SARS-CoV-2 in the Air

Researchers at Switzerland-based Empa, ETH Zurich and Zurich University Hospital have developed a sensor that has the potential to identify SARS-CoV-2, the novel coronavirus that causes COVID-19, in the air. The work is led by Jing Wang at Empa, who usually works on measuring and analyzing airborne pollutants. The sensor has reliably shown it can identify the first SARS-CoV virus that was responsible for the SARS pandemic in 2003. It has numerous similarities to SARS-CoV-2. Tests showed that the sensor can clearly distinguish between the very similar RNA sequences of the two viruses, Jing Wang said. And the results appear in minutes.

Possible Gene Therapy for Glaucoma

Glaucoma is a common condition of the eye involved fluid buildup in the front part of the eye. It affects more than 64 million people globally and is the leading cause of irreversible blindness. Current treatments include eye drops, laser or surgery. Researchers at the University of Bristol demonstrated that a single injection of a gene therapy using CRISPR and a gene called Aquaporin 1 targeting the ciliary body, where fluid is produced within the eye, led to reduced eye pressure.

More Evidence Parkinsons is an Autoimmune Disease

A study co-led by investigators at the La Jolla Institute for Allergy and Immunology (LJI) adds to the theory that Parkinsons disease is at least partly an autoimmune disease. The research was published in Nature Communications. Science has known for some time that the clumps of a damaged protein known as alpha-synuclein build up in the dopamine-producing brain cells of Parkinsons disease patients. The clumps lead to death of the cells and cause motor symptoms and cognitive decline.

Once these cells are gone, theyre gone, said Cecilia Lindestam Arlehamn, first author of the study and LJI research assistant professor. So if you are able to diagnose the disease as early as possible, it could make a huge difference.

A 2017 study showed that alpha-synuclein attracted certain type of T-cells, causing them to mistakenly attack brain cells, which potentially contributed to the progression of Parkinsons. The new findings found that the T-cells that react to alpha-synuclein are the most abundant when patients are first diagnosed with the disease. They tend to disappear later in the disease and by 10 years after diagnosis, few patients still have them.

This tells us that detection of T-cell responses could help in the diagnosis of people at risk or in early stages of disease development, when many of the symptoms have not been detected yet, said LJI professor Alessandro Sette, who co-led the research with David Sulzer of the Columbia University Medical Center. Importantly, we could dream of a scenario where early interference with T-cell responses could prevent the disease from manifesting itself or progressing.

View original post here:
Research Roundup: New Protein Linked to Alzheimer's Identified and More - BioSpace

Recommendation and review posted by Bethany Smith

The world is not only fighting a health pandemic but also an economic one, as the Novel Coronavirus (COVID 19) casts its long shadow over economies around the globe. The complete lockdown situation in several countries, has directly or indirectly impacted many industries causing a shift in activities like supply chain operations, vendor operations, product commercialization, etc. In the latest report on Crispr And Crispr Associated Genes Market, published by Market Research Intellect, numerous aspects of the current market scenario have been taken into consideration and a concise analysis has been put together to bring you with a study that has Pre- and Post-COVID market analysis. Our analysts are watching closely, the growth and decline in each sector due to COVID 19, to offer you with quality services that you need for your businesses. The report encompasses comprehensive information pertaining to the driving factors, detailed competitive analysis about the key market entities and relevant insights regarding the lucrative opportunities that lie in front of the industry players to mitigate risks in such circumstances.

It offers detailed research and analysis of key aspects of the global Crispr And Crispr Associated Genes market. The market analysts authoring this report has provided detailed information on growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Crispr And Crispr Associated Genes market. Market participants can use the market analysis to plan effective growth strategies and prepare for future challenges in advance. Each trend in the global Crispr And Crispr Associated Genes market is carefully analyzed and investigated by market analysts.

For Better Understanding, Download Sample PDF Copy of Crispr And Crispr Associated Genes Market Research Report @ https://www.marketresearchintellect.com/download-sample/?rid=202013&utm_source=LHN&utm_medium=888

**Our SAMPLE COPY of the report gives a brief introduction of the Crispr And Crispr Associated Genes market, Detailed TOC, key players of the market, list of tables and figures and comprising key countries regions.**

The Major Players in Global Crispr And Crispr Associated Genes Market:

Global Crispr And Crispr Associated Genes Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=202013&utm_source=LHN&utm_medium=888

Crispr And Crispr Associated Genes Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Crispr And Crispr Associated Genes industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Crispr And Crispr Associated Genes industry.

-> Furthermore, we will help you to identify any crucial trends to predict Crispr And Crispr Associated Genes market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Crispr And Crispr Associated Genes market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=202013&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Crispr And Crispr Associated Genes market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Crispr And Crispr Associated Genes market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Crispr And Crispr Associated Genes Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Crispr And Crispr Associated Genes Market Size, Crispr And Crispr Associated Genes Market Growth, Crispr And Crispr Associated Genes Market Forecast, Crispr And Crispr Associated Genes Market Analysis

Our Trending Reports

Construction Adhesives Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Textile Enzymes Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Acetaldehyde Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See original here:
Crispr And Crispr Associated Genes Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

Recommendation and review posted by Bethany Smith

Central to a lot of scientific research into aging are tiny caps on the ends of our chromosomes called telomeres. These protective sequences of DNA grow a little shorter each time a cell divides, but by intervening in this process, researchers hope to one day regulate the process of aging and the ill health effects it can bring. A Harvard team is now offering an exciting pathway forward, discovering a set of small molecules capable of restoring telomere length in mice.

Telomeres can be thought of like the plastic tips on the end of our shoelaces, preventing the fraying of the DNA code of the genome and playing an important part in a healthy aging process. But each time a cell divides, they grow a little shorter. This sequence repeats over and over until the cell can no longer divide and dies.

This process is linked to aging and disease, including a rare genetic disease called dyskeratosis congenita (DC). This is caused by the premature aging of cells and is where the Harvard University team focused its attention, hoping to offer alternatives to the current treatment that involves high-risk bone marrow transplants and which offers limited benefits.

One of the ways dyskeratosis congenita comes about is through genetic mutations that disrupt an enzyme called telomerase, which is key to maintaining the structural integrity of the telomere caps. For this reason, researchers have been working to target telomerase for decades, in hopes of finding ways to slow or even reverse the effects of aging and diseases like dyskeratosis congenita.

Once human telomerase was identified, there were lots of biotech startups, lots of investment, says Boston Childrens Hospital's Suneet Agarwal, senior investigator on the new study. But it didnt pan out. There are no drugs on the market, and companies have come and gone.

Agarwal has been studying the biology of telomerase for the past decade, and back in 2015 he and his team discovered a gene called PARN that plays a role in the action of the telomerase enzyme. This gene normally processes and stabilizes an important component of telomerase called TERC, but when it mutates, it results in less of the enzyme being produced and, in turn, the telomeres becoming shortened prematurely.

For the new study, Harvard researchers screened more than 100,000 known chemicals in search of compounds that could preserve healthy function of PARN. This led them to small handful that seemed capable of doing so by inhibiting an enzyme called PAPD5, which serves to unravel PARN and destabilize TERC.

We thought if we targeted PAPD5, we could protect TERC and restore the proper balance of telomerase, says Harvard Medical Schools Neha Nagpal, first author on the new paper.

These chemicals were tested on stem cells in the lab, made from the cells of patients with dyskeratosis congenita. These compounds boosted TERC levels in those stem cells and restored telomeres to their normal length. However, rather than a scattergun approach, the team really wanted to test for safety and see if the treatment could precisely target stem cells carrying the right ingredients for telomerase formation.

More specifically, the team wanted to see if this could be achieved by having the PAPD5-inhibiting drugs recognize and respond to another important component of telomerase, a molecule called TERT. To do so, in the next round of experiments the team used human blood stem cells and triggered mutations in the PARN gene that give rise to dyskeratosis congenita. These were then implanted into mice that were treated with the compounds, with the team finding the treatment boosted TERC, restored telomere length in the stem cells and had no ill effects on the rodents.

This provided the hope that this could become a clinical treatment, says Nagpal.

The team will now continue its work in an effort to prove these small molecules are a safe and effective way to apply the brakes to dyskeratosis congenita, other diseases, and possibly aging more broadly.

We envision these to be a new class of oral medicines that target stem cells throughout the body, Agarwal says. We expect restoring telomeres in stem cells will increase tissue regenerative capacity in the blood, lungs, and other organs affected in DC and other diseases.

The research was published in the journal Cell Stem Cell.

Source: Boston Childrens Hospital via Harvard University

See the original post here:
Molecules identified that reverse cellular aging process - New Atlas

Recommendation and review posted by Bethany Smith

The Irish Cattle Breeding Federation (ICBF) has released data analysing the births from the dairy herd. There have been a number of interesting trends emerging with the analysis covering a five-year period from 2016 to 2020.

Firstly, one of the most notable trends is the decline in the use of Jersey genetics in the national dairy herd.

After several years of steady growth, there was a significant decline in 2019, resulting in a 17.3% reduction in the number of Jersey-bred calves born for the year-to-date. This clearly reflects the challenges associated with finding markets for lower-value Jersey male calves.

In spring 2019, some 41,000 Jersey-bred calves were born on Irish farms; however, this has fallen to just over 34,200 calves in 2020 and this is predicted to decrease further in spring 2021.

Secondly, the use of beef genetics in the dairy herd has increased by 7% from 2019 to 2020, and by just over 36% over the five-year period; this is welcome news for the beef industry.

As expected, both Aberdeen Angus and Hereford continue in first and second position respectively, accounting for 78% in total, but other beef breeds have witnessed growth albeit from a much lower base.

Leaving Angus and Hereford aside, Limousin-sired calves are placed in third position with some 37,923 calves on the ground to date an increase of 5% on 2019 levels.

The Belgian Blue breed is next with some 19,744 calves born up to April 16; this represents a jump of just under 4,000 calves or an increase of 25.4%.

Finally, the beef breed which increased the most was the Aubrac, with some 7,277 calves born on Irish dairy farms a 55.3% increase from 2019.

RELATED STORIES

See the rest here:
Jersey usage in the dairy herd declines by over 17% - Agriland

Recommendation and review posted by Bethany Smith

(Photo by John Korduner/Icon Sportswire)

With the 10th pick in the 2020 NFL Draft, the Cleveland Browns selected offensive tackle Jedrick Wills.

The Browns did not anticipate Wills slipping to No.10 and were thrilled to get him.

The #Browns had trade offers, but so far no trades: A tackle they didnt think was going to be here at No. 10 is available: #Bama OT Jedrick Wills. A mean, nasty tackle.

Ian Rapoport (@RapSheet) April 24, 2020

Wills is completing his junior year at the University of Alabama.

He becomes the 7th first-round offensive lineman drafted under Head Coach Nick Saban at Alabama.

Wills is a consistent performer who tallied 28 consecutive starts at Alabama.

At right tackle, his speed and athleticism were an asset to his QB Tua Tagovailoa.

Tua described Jedrick as the alpha male and the guy capable of making things happen on the field.

Cleveland #Browns new OT Jedrick Wills Jr. pic.twitter.com/VP8LCzQCJR

Everything Cleveland (@EverythingCLE_) April 24, 2020

The newest Cleveland Brown has a fascinating background.

Here are 3 things to know about him.

Though Jedrick Wills played football during his formative years, he always felt basketball was the sport he would ultimately succeed in playing.

He aspired to be a point guard.

As a sophomore at Lafayette High School, Wills broke a bone in his foot.

At that time, he made a decision to focus on football.

Measured at 6 5 and weighing 320 pounds, it seems Wills made the right choice.

His high school football coach, former Cincinnati Bengals linebacker Eric Shaw, agreed.

After making the All-State team in his junior and senior years of high school, Wills was invited to play in the Under Armour All-America Game.

This is a showcase game for the top high school senior football players in the country.

It is played in Florida each January.

Wills entertained offers from neighboring University of Kentucky, Notre Dame, Michigan, Tennessee, and Alabama.

He was conflicted because he really wanted to stay home and play football because he believed that is what most did who were born and raised in Kentucky.

The UK campus was only 5 minutes from his high school, and he went on 8 recruiting visits there until he reached a decision.

An encounter during his freshman year with a former top prospect from Kentucky, Damien Harris, stuck in his mind.

I knew Jed before we both got here, Harris said. We had a little bit of a relationship. Obviously when I committed here and ended up coming here and he was looking at coming here and hes looking at a bunch of other schools, I always kept in touch with him and see how he felt about our program and obviously tried to encourage him to come here. And fortunately enough, he did.

Its a bit of an unlikely pairing: Theyre the two highest-rated players from the state of Kentucky in the last decade, according to the 247Sports Composite ratings. They ended up playing together, but did so several hours from home.

It was pretty cool, Wills said. Being from Kentucky, theres not really too many people who go outside the state and go to like real big schools. Seeing he had that opportunity kind of opened up my eyes. I could see I had the chance to do the same thing.

Harris also had offers from many schools including UK.

At the time when the two met, Harris was committed to the University of Michigan but ultimately changed his mind and ended up playing for Nick Saban at Alabama.

The reason Jedrick Wills believed basketball was his sport is largely due to his genetics.

His father, Jedrick Wills Sr. is the assistant womans basketball coach at Lafayette High School.

Sivi Wills, his mother, played basketball at Eastern Kentucky.

Surprisingly his mother was influential in his decision to focus on football.

She recognized that the combination of his size and speed made him a force to reckon with on the football field.

Jedrick Wills was a no-brainer choice for the Cleveland Browns at #10.

He is an established right tackle known as a dog for his punishing tackles.

Wills will likely be asked to switch to left tackle with the express purpose of protecting Baker Mayfields blind side.

And the good news is that he will have future Hall of Fame help in doing so.

#Browns Kevin Stefanski said Joe Thomas will be a resource as Jedrick Wills makes switch to left tackle.

Scott Petrak ct (@ScottPetrak) April 24, 2020

Jedrick Wills will be a welcome addition to the Cleveland Browns this fall.

See the original post:
3 Things To Know About 1st Round Draft Pick Jedrick Wills - Browns Nation

Recommendation and review posted by Bethany Smith